Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
April 18 Product: Genentechs Alecensa Indication: Non-small cell lung cancer The FDA approved Genentechs Alecensa Thursday as the first adjuvant treatment for patients with early-stage, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have undergone tumor resection
The PCAC is an advisory body
2016 May-Jun;82(3):262-72
How many randomised, placebo-controlled human trials exist in your specific population
Regulation of Sirt1 on energy metabolism and immune response in rheumatoid arthritis
AHK-Cu seems to bridge the gap between simple peptides and more complex bioactive molecules, showing activity in wound healing, anti-inflammatory regulation, and perhaps even neuroprotection
US$ 22.78
US$ 28.77
US$ 23.34
